Ascletis PharmaASCLF -4.00%38 Current Ratio is 15.05 as of Dec. 2025, which is 25% below its 10-year median of 20.05. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Ascletis Pharma ranks better than 86.82% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ascletis Pharma's current ratio for the quarter that ended in Dec. 2025 was 15.05.
Ascletis Pharma has a current ratio of 15.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Ascletis Pharma's Current Ratio or its related term are showing as below:
ASCLF'
s Current Ratio Range Over the Past 10 Years
Min: 6.35 Med: 20.05 Max: 38.36
Current: 15.05
During the past 10 years, Ascletis Pharma's highest Current Ratio was 38.36. The lowest was 6.35. And the median was 20.05.
ASCLF's Current Ratio is ranked better than 86.82% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ASCLF: 15.05
Ascletis Pharma (OTCPK:ASCLF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ascletis Pharma Current Ratio Related Terms
Ascletis Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Ascletis Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Current Ratio of 15.05 as of Dec. 2025. This is 25% below median its historical median of 20.05. Over the past decade, Ascletis Pharma's Current Ratio has ranged from 6.35 to 38.36. According to the industry distribution chart, Ascletis Pharma ranks #186 out of 1411 companies in the Biotechnology industry, placing it in the top 13.2%.
Is Ascletis Pharma's Current Ratio too high?
Ascletis Pharma's current Current Ratio of 15.05 is 25% below median its 10-year median of 20.05. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 38.36. The Biotechnology industry median Current Ratio is 3.88. Ascletis Pharma's value of 15.05 is 287.9% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #186 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #186 out of 1411 companies for Current Ratio. This places Ascletis Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Ascletis Pharma's value of 15.05 is 287.9% above this benchmark. Historically, Ascletis Pharma's own Current Ratio has ranged from 6.35 to 38.36 over the past decade. While the company's 10-year median is 20.05 vs. the industry median of 3.88, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Current Ratio of 15.05 is 287.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Current Ratio is 15.05, which is 25% below median its own 10-year median of 20.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Current Ratio is 15.05, which is 25% below median its 10-year median of 20.05 and 287.9% above the Biotechnology industry median of 3.88. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Current Ratio is 15.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Current Ratio: 15.05 (25% below median its 10-year median of 20.05)
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 287.9% above the Biotechnology median (#186 of 1411)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
